Kairos Pharma (NYSEAMERICAN:KAPA) Issues Earnings Results

Kairos Pharma (NYSEAMERICAN:KAPA) posted its quarterly earnings data on Wednesday. The company reported ($0.06) earnings per share (EPS) for the quarter, FiscalAI reports.

Kairos Pharma Stock Performance

KAPA stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.35. 244,045 shares of the stock traded hands, compared to its average volume of 1,125,347. Kairos Pharma has a one year low of $0.27 and a one year high of $2.11. The stock has a market capitalization of $7.59 million, a PE ratio of -1.18 and a beta of 1.56. The business has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.52.

Hedge Funds Weigh In On Kairos Pharma

An institutional investor recently bought a new stake in Kairos Pharma stock. XTX Topco Ltd acquired a new stake in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned about 0.31% of Kairos Pharma as of its most recent SEC filing.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.